ASH 2022 Conference Coverage

 

Myeloma
07:05

ASH 2022 Conference Coverage

ASH 2022 Phase 1/2 Results From MonumenTAL-1: Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in R/R MM

FEATURING Ajai Chari
  • 206 views
  • August 14, 2023
  • 2
07:25

ASH 2022 Conference Coverage

ASH 2022 Results of the ASCENT Trial: Fixed Duration Therapy With Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone for High-Risk Smoldering MM

FEATURING Shaji Kumar
  • 79 views
  • February 22, 2023
10:37

ASH 2022 Conference Coverage

ASH 2022 Mezigdomide (CC-92480) + Dex in R/R MM: Preliminary Results From the Dose Expansion Phase of the CC-92480-MM-001 Trial

FEATURING Paul Richardson
  • 178 views
  • February 16, 2023
24:01

ASH 2022 Conference Coverage

ASH 2022: First Relapse in Multiple Myeloma - How to Pick the Next Best Thing

FEATURING Yvonne Efebera
  • 225 views
  • January 28, 2023
07:37

ASH 2022 Conference Coverage

IKEMA Subgroup Analysis: Isatuximab + Carfilzomib & Dexamethasone in Patients With Early vs. Late Relapsed MM

FEATURING Thomas Martin
  • 1,481 views
  • January 20, 2023
  • 3
10:37

ASH 2022 Conference Coverage

ASH 2022 Subsequent Antimyeloma Therapies From ICARIA-MM Study: Pom/Low-Dose Dex +/- Isa in Patients With R/R Myeloma

FEATURING Paul Richardson
  • 109 views
  • January 18, 2023
  • 2
06:25

ASH 2022 Conference Coverage

ASH 2022 Phase 3 EMagine/CARTITUDE-6 Trial: DVRd Followed by either Cilta-Cel or ASCT in Transplant-Eligible NDMM

FEATURING Pieter Sonneveld
  • 122 views
  • January 18, 2023
11:25

ASH 2022 Conference Coverage

ASH 2022 MAIA Trial Age Subgroup Analysis: Daratumumab + Lenalidomide & Dexamethasone in Transplant-Ineligible NDMM

FEATURING Torben Plesner
  • 81 views
  • January 13, 2023
15:03

ASH 2022 Conference Coverage

ASH 2022: A Consultant’s Guide to Smoldering Multiple Myeloma

FEATURING Sigrun Thorsteinsdottir
  • 135 views
  • January 11, 2023
04:10

ASH 2022 Conference Coverage

ASH 2022 SubQ Isatuximab + Carfilzomib & Dexamethasone in Relapsed MM: Ikema Subgroup Analysis by Number of Prior Lines of Treatment

FEATURING Hang Quach
  • 170 views
  • January 4, 2023
20:46

ASH 2022 Conference Coverage

ASH 2022 Understanding and Monitoring Resistance to Anti-CD38 and -BCMA Therapies

FEATURING Flavia Pichiorri
  • 203 views
  • January 4, 2023
11:12

ASH 2022 Conference Coverage

ASH 2022 Gene Edited Off-the-Shelf NK Cells for Treating Hematologic Disease

FEATURING Jeffrey Miller
  • 80 views
  • January 4, 2023
05:18

ASH 2022 Conference Coverage

ASH 2022 Phase II DEDALO Trial: Daratumumab + Pomalidomide & Dexamethasone (DPd) in Patients With R/R MM and 17p Deletion

FEATURING Vittorio Montefusco
  • 43 views
  • December 28, 2022
  • 1
14:16

ASH 2022 Conference Coverage

Assessing Disease Risk in Multiple Myeloma: High or Low?

FEATURING Timothy Schmidt
  • 142 views
  • December 28, 2022
  • 2
03:00

ASH 2022 Conference Coverage

ASH 2022 Phase 1 MagnetisMM-1 Trial: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical & Molecular Responses for Patients With R/R MM

FEATURING Noopur S. Raje
  • 64 views
  • December 22, 2022
06:16

ASH 2022 Conference Coverage

U.S. Myeloma CAR-T Consortium Real World Experience: Factors Associated With Refractoriness or Early Progression After Ide-Cel in Pts With R/R MM

FEATURING Hamza Hashmi
  • 217 views
  • December 22, 2022
  • 1
08:24

ASH 2022 Conference Coverage

ASH 2022 Once Weekly Selinexor, Carfilzomib & Dexamethasone (XKd) in Triple-Class Refractory MM

FEATURING Gary Schiller
  • 52 views
  • December 22, 2022
10:08

ASH 2022 Conference Coverage

ASH 2022 Maintenance Therapy Cessation for Sustained MRD Negative MM Patients

FEATURING Neha Korde
  • 412 views
  • December 21, 2022
  • 2
10:34

ASH 2022 Conference Coverage

ASH 2022 Phase 1/2 LINKER-MM1 Study of Linvoseltamab, a BCMAxCD3 Bispecific Antibody, for the Treatment of R/R MM: Updated Safety and Efficacy

FEATURING Naresh Bumma
  • 91 views
  • December 21, 2022
  • 1
07:17

ASH 2022 Conference Coverage

ASH 2022 Phase 3 VITAL Study: Survival Benefit of Birtamimab in Mayo Stage IV AL Amyloidosis Consistent After Adjustment for Key Baseline Variables

FEATURING Morie Gertz
  • 78 views
  • December 19, 2022
  • 1
05:05

ASH 2022 Conference Coverage

ASH 2022 Outcomes of Penta-Refractory MM Patients Based on Access to BCMA-Directed Therapy

FEATURING Shebli Atrash
  • 136 views
  • December 19, 2022
  • 2
15:32

ASH 2022 Conference Coverage

Novel Approaches to Myeloma Burden Assessment

FEATURING Taxiarchis Kourelis
  • 261 views
  • December 19, 2022
  • 2
14:03

ASH 2022 Conference Coverage

ASH 2022 Neurotoxicity With Motor Symptoms After BCMA-Directed CAR-T Therapy in MM

FEATURING Samir Parekh
  • 74 views
  • December 16, 2022
  • 1
05:56

ASH 2022 Conference Coverage

ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalidomide Maintenance After ASCT

FEATURING Gareth Morgan
  • 906 views
  • December 16, 2022
  • 6
14:23

ASH 2022 Conference Coverage

ASH 2022 Phase I Dose-Escalation Study of Forimtamig (RG6234), a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody in R/R MM: Updated IV and First SC Results

FEATURING Carmelo Carlo-Stella
  • 55 views
  • December 16, 2022
04:31

ASH 2022 Conference Coverage

ASH 2022 GRIFFIN Trial Final Analysis: D-RVd in Clinically Relevant Subgroups of Transplant-Eligible Newly Diagnosed MM

FEATURING Ajai Chari
  • 768 views
  • December 16, 2022
  • 5